Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
Open Access
- 8 April 2019
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-10
Abstract
To establish a nomogram for predicting the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM), 304 patients with newly diagnosed MM were recruited between June 1, 2010, and June 30, 2015, from the Beijing Chaoyang Hospital, Capital Medical University, and randomly divided into training (n=214) and validation (n=90) cohorts. The Kaplan-Meier method and the Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinical and laboratory parameters on survival. Significant prognostic factors were combined to build a nomogram. The discriminative ability and predictive accuracy of the nomogram were evaluated using the index of concordance (C-index) and calibration curves and compared with the five staging systems currently used for MM. Multivariate analysis of the training cohort revealed that the age at diagnosis, clonal bone marrow plasma cells, serum lactate dehydrogenase, serumβ2-microglobulin, and del (17p) were independent risk factors for OS and were used to establish the nomogram. The C-index value of the nomogram for predicting OS was 0.749, which was significantly higher than the C-indices of the five most common staging systems currently used for MM. In the validation cohort, the C-index for nomogram-based predictions was 0.711 for OS, and the nomogram discrimination was better than the above mentioned five staging systems (P<0.001). All calibration curves revealed good consistency between predicted and actual survivals. The proposed nomogram is more accurate in predicting the prognoses of patients with newly diagnosed MM.Keywords
This publication has 33 references indexed in Scilit:
- Multiple MyelomaNew England Journal of Medicine, 2011
- The prognostic significance of cytogenetics and molecular profiling in multiple myelomaCancer Genetics, 2011
- Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?Journal of Clinical Oncology, 2010
- Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple MyelomaJournal of Clinical Oncology, 2010
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus GuidelinesMayo Clinic Proceedings, 2009
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaBlood, 2008
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood, 2008
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006